DigestRedComo funciona
Red
/
Empresas
No
No verificado

Novartis Pharma AG

Sobre qué escribimos

Anuncios brevesFarmacéuticaGestión empresarial/Administración de EmpresasMedicina Salud BienestarPublicidad/Marketing/Medios de comunicación/Comunicación

73 Comunicados de prensa

Ver todos los comunicados de prensa
16/01/2026
Farmacéutica
Anuncios breves
Novartis ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
09/01/2026
Farmacéutica
Anuncios breves
Novartis to add radioligand therapy manufacturing facility in Winter Park, Florida, fourth in US to serve patients and advance $23 billion investment
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
19/12/2025
Farmacéutica
Anuncios breves
Novartis and US government reach agreement on lowering drug prices in the US
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
09/12/2025
Farmacéutica
Anuncios breves
Novartis ianalumab significantly extends disease control in patients with immune thrombocytopenia with only four once-monthly doses
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
09/12/2025
Farmacéutica
Anuncios breves
1 in 4 metastatic breast cancer patients treated with Novartis Kisqali® remain progression-free beyond 4 years
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
24/11/2025
Farmacéutica
Anuncios breves
Novartis data underscore pioneering scientific innovation in Hematology and Oncology at ASH and SABCS
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
24/11/2025
Farmacéutica
Medicina Salud Bienestar
Anuncios breves
Novartis receives FDA approval for Itvisma®, the only gene replacement therapy for children two years and older, teens, and adults with spinal muscular atrophy (SMA)
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
19/11/2025
Farmacéutica
Anuncios breves
Novartis projects +5-6% cc sales CAGR 2025-2030, with long-term growth backed by 30+ potential high-value pipeline assets
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
19/11/2025
Farmacéutica
Anuncios breves
Novartis announces plans to build flagship manufacturing hub in North Carolina
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0
12/11/2025
Farmacéutica
Anuncios breves
Novartis Phase III trial for next-generation malaria treatment KLU156 (GanLum) meets primary endpoint, with potential to combat antimalarial resistance
Fuente
Novartis Pharma AG
Editor
GLOBENEWSWIRE
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0